Raphael Pharmaceutical (RAPH) Long-Term Deferred Tax (2020 - 2021)
Raphael Pharmaceutical's (RAPH) quarterly Long-Term Deferred Tax came in at $1.2 million in Q4 2021, up 686.71% year-on-year from $158000.0 in Q4 2020, and up 686.71% quarter-over-quarter from $158000.0 in Q4 2020.
Raphael Pharmaceutical (RAPH) Long-Term Deferred Tax (2020 - 2021) Analysis & Trends
Raphael Pharmaceutical has disclosed Long-Term Deferred Tax across 2 years of filings, most recently posting $1.2 million for Q4 2021.
- Long-Term Deferred Tax for Q4 2021 came in at $1.2 million, up 686.71% year-over-year; the trailing twelve-month figure through Dec 2021 was $1.2 million (up 686.71% YoY), and the FY2021 annual result was $1.2 million, up 686.71% from the prior year.
- Long-Term Deferred Tax came in at $1.2 million for Q4 2021 at Raphael Pharmaceutical, up from $158000.0 in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $1.2 million in Q4 2021 to a low of $158000.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn |
| 10 | Raphael Pharmaceutical | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 1.24 Mn |
| Dec 31, 2020 | 158,000.00 |